The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Abbott Laboratories is hoping to broaden its reach by appealing to healthy consumers with its new wearable device called Lingo. CEO Robert Ford said Abbott will continue to solve medical problems, ...

Abbott broadens cancer diagnostics portfolio through Exact Sciences acquisition; Focus strengthens position within advanced ...

Shares of Abbott Laboratories (ABT) have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences Corporation (EXAS), taking place at a revenue ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

Abbott Laboratories narrowed its full-year outlook as sales of COVID-19 tests slide. COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...

A concussion test that Abbott Labs hopes someday could be used by sports team trainers and at urgent care clinics is now available for rapid use at the bedside, without having to send a sample to a ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...